Novartis' eye drug Lucentis has been granted with a new indication by the European Commission (EC). Lucentis (ranibizumab) is now approved to treat patients with visual impairment due to choroidal ...

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are ...

Lucentis was developed by Genentech, a member of the Roche Group. The company retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world.

Roche subsidiary Genentech makes both of the drugs, but Lucentis is licensed to Novartis for marketing purposes, while Avastin is marketed by Roche. Italy’s competition authority determined that the ...

While Novartis’ newer drugs largely beat expectations, some older products such as eye injection Lucentis fell short, he said ...

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

Wet AMD is primarily treated with drugs that target vascular endothelial growth factor, such as ranibizumab (Lucentis; Genentech/Novartis), which inhibit the growth of abnormal new blood vessels ...